Your browser doesn't support javascript.
loading
Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation.
Teshigawara-Tanabe, Haruka; Hagihara, Maki; Aoki, Jun; Koyama, Satoshi; Takahashi, Hiroyuki; Nakajima, Yuki; Kunimoto, Hiroyoshi; Tachibana, Takayoshi; Miyazaki, Takuya; Matsumoto, Kenji; Tanaka, Masatsugu; Yamazaki, Etsuko; Fujisawa, Shin; Kanamori, Heiwa; Taguri, Masataka; Nakajima, Hideaki.
Afiliación
  • Teshigawara-Tanabe H; Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Hagihara M; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Aoki J; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Koyama S; Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
  • Takahashi H; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Nakajima Y; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Kunimoto H; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Tachibana T; Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Miyazaki T; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Matsumoto K; Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
  • Tanaka M; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Yamazaki E; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Fujisawa S; Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
  • Kanamori H; Department of Laboratory Medicine, Yokohama City University Hospital, Yokohama, Japan.
  • Taguri M; Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
  • Nakajima H; Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Hematology ; 27(1): 620-628, 2022 Dec.
Article en En | MEDLINE | ID: mdl-35621915
Objectives: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only curative treatment for myelodysplastic syndromes (MDS), although predicting post-transplant outcomes remains inconclusive. This study evaluated patients who underwent allo-HCT for MDS to identify prognostic factors and develop a clinical risk model.Methods: We evaluated 55 patients between June 2000 and March 2015 to identify prognostic factors and develop a model for three-year overall survival (OS) and event-free survival (EFS). Cox regression analysis was performed on four factors: age ≥55 years; Hematopoietic Cell Transplant-Comorbidity Index >2; intermediate or worse cytogenetic status based on revised International Prognostic Scoring System; and unrelated donor status associated with poor OS in the univariate analysis. A clinical risk model was constructed using the sum of the regression coefficients and evaluated using receiver operating characteristic analysis and five-fold cross-validation.Results: Patient median age was 51 (range: 30-67) years. Median follow-up was 45.8 (range: 1.27-193) months; the three-year OS and EFS rates were 61.8% and 56.4%, respectively. The areas under the curves (AUCs) for OS and EFS were 0.738 and 0.778, respectively, and the average AUC for 50 times five-fold cross-validation were 0.711 and 0.723 for three-year OS and EFS, respectively.Conclusion: A four-clinical-risk-factor model that could effectively predict post-transplantation outcomes and help decision-making in MDS treatment was developed.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Middle aged Idioma: En Revista: Hematology Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Middle aged Idioma: En Revista: Hematology Asunto de la revista: HEMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido